Invention Application
- Patent Title: Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
- Patent Title (中): 用于改善抗体依赖性细胞毒性的抗体的糖基化工程
-
Application No.: US10633697Application Date: 2003-08-05
-
Publication No.: US20050079605A1Publication Date: 2005-04-14
- Inventor: Pablo Umana , Joel Jean-Mairet , James Bailey
- Applicant: Pablo Umana , Joel Jean-Mairet , James Bailey
- Assignee: Glycart Biotechnology AG
- Current Assignee: Glycart Biotechnology AG
- Main IPC: C12N15/09
- IPC: C12N15/09 ; A61K39/395 ; A61P35/00 ; C07H21/04 ; C07K16/00 ; C07K16/28 ; C07K16/30 ; C12N1/15 ; C12N1/19 ; C12N1/21 ; C12N5/10 ; C12P21/00 ; C12P21/08 ; C12N5/06
Abstract:
The present invention relates to the field glycosylation engineering of proteins. More particular, the present invention is directed to the glycosylation engineering of proteins to provide proteins with improved therapeutic properties, e.g., antibodies, antibody fragments, or a fusion protein that includes a region equivalent to the Fc region of an immunoglobulin, with enhanced Fc-mediated cellular cytotoxicity.
Public/Granted literature
- US07517670B2 Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity Public/Granted day:2009-04-14
Information query
IPC分类:
